Compared to Estimates, Bristol Myers (BMY) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/27/23
Bristol Myers Squibb (BMY) Misses Q2 Earnings and Revenue EstimatesZacks Investment Research • 07/27/23
Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid salesMarket Watch • 07/27/23
The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical IndustrySeeking Alpha • 07/21/23
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaBusiness Wire • 07/21/23
Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 07/20/23